Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
Abstract Background Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established m...
Main Authors: | Charlott Mörth, Amal Abu Sabaa, Eva Freyhult, Christina Christersson, Jamileh Hashemi, Nashmil Hashemi, Masood Kamali-Moghaddam, Daniel Molin, Martin Höglund, Anna Eriksson, Gunilla Enblad |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | Cardio-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40959-021-00092-0 |
Similar Items
-
Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma
by: Dino Amadori
Published: (2011-10-01) -
Follicular lymphoma: treatment and prognostic factors
by: Stefano Luminari, et al.
Published: (2012-01-01) -
Molecular mechanisms of apoptosis induction in murine lymphoma NK/Ly under chemotherapy in vivo
by: R. R. Panchuk, et al.
Published: (2009-04-01) -
Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
by: Camille Cotteret, et al.
Published: (2020-04-01) -
Ongoing trials in low-grade lymphoma
by: Alexander Burchardt
Published: (2011-10-01)